Immunitybio Inc (IBRX)

$7.78 +0.18 (2.37%)
Market Cap 7.81B
Revenue (ttm) 113.29M
Net Income (ttm) -351.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -310.18%
Debt to Equity Ratio 0.00
Volume 10,501,900
Avg Vol 29,339,254
Day's Range N/A - N/A
Shares Out 1.03B
Stochastic %K 96%
Beta 0.13
Analysts Strong Sell
Price Target $14.80

Company Profile

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 696 5235
Address:
3530 John Hopkins Court, San Diego, United States
Alex2528
Alex2528 Apr. 16 at 9:11 AM
$IBRX shorts already shorting…
0 · Reply
Arztzeze
Arztzeze Apr. 16 at 9:07 AM
$IBRX who remembers the green candles ending december into january. When we were at 2. The daily small candles...i have a strong believe we are going into such daily greens again...the markets will look funny early ...then eventually produce a small daily green to end the day...i am in for the ride...FDA is exposed, the data speaks for itself, the revenue are coming strong...IL 15 is the standard and no other company does it better than IBRX.
0 · Reply
De12
De12 Apr. 16 at 9:04 AM
$IBRX $IOVA $ADMA Get that Greeen!!
0 · Reply
BeMarsh
BeMarsh Apr. 16 at 8:52 AM
$IBRX good morning from Kirtland Hills, Ohio
1 · Reply
CAVALRY_37748
CAVALRY_37748 Apr. 16 at 8:50 AM
$IBRX Good morning IBRX, From the looks of it the shorts are already trying to set it up to keep it below the 7.50 mark. Please stop buying options that you can't cash in on. It's clearly a manipulated market. If we all keep buying small amounts everyday we will win the price war. The produst is too good not to win. It could mean generational wealth.
0 · Reply
ghcb1981
ghcb1981 Apr. 16 at 8:47 AM
$IBRX
0 · Reply
Ulaughing
Ulaughing Apr. 16 at 8:37 AM
$IBRX Good morning you lovely people, and happy Thursdays. Me thinks today could be just a little bit spicy 🌶️ ❤️
0 · Reply
Marcanwin2025
Marcanwin2025 Apr. 16 at 8:18 AM
$IBRX Get your buys today in the "lit" market. It helps the charts. Call your broker.
0 · Reply
Dirtyhope
Dirtyhope Apr. 16 at 8:17 AM
$IBRX
0 · Reply
Nfty
Nfty Apr. 16 at 8:08 AM
$IBRX just getting started IL-15 reactivated stalled immunity, restoring cytokine sequencing, driving NK/CD8 response, clearing pathogens, and enabling tissue repair—transforming immune paralysis into coordinated, effective defense.
0 · Reply
Latest News on IBRX
REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026

Apr 15, 2026, 8:00 PM EDT - 9 hours ago

REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026

ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Apr 15, 2026, 9:36 AM EDT - 19 hours ago

ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your Rights

IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

Apr 14, 2026, 4:35 PM EDT - 1 day ago

IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline

Apr 14, 2026, 11:14 AM EDT - 1 day ago

IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

Apr 14, 2026, 9:50 AM EDT - 1 day ago

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

Why Is ImmunityBio Stock Rallying Thursday?

Apr 9, 2026, 2:11 PM EDT - 6 days ago

Why Is ImmunityBio Stock Rallying Thursday?

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

Apr 9, 2026, 7:30 AM EDT - 6 days ago

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role

Apr 8, 2026, 6:00 PM EDT - 7 days ago

IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

Apr 6, 2026, 7:30 AM EDT - 9 days ago

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

Apr 1, 2026, 4:07 PM EDT - 14 days ago

ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

Mar 31, 2026, 7:30 AM EDT - 15 days ago

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

Mar 27, 2026, 12:17 PM EDT - 19 days ago

$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

Mar 26, 2026, 10:04 AM EDT - 20 days ago

ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

Mar 26, 2026, 7:30 AM EDT - 20 days ago

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

ImmunityBio stock price crash: buy the dip or sell the rip?

Mar 24, 2026, 3:25 PM EDT - 22 days ago

ImmunityBio stock price crash: buy the dip or sell the rip?

ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 24, 2026, 12:56 PM EDT - 22 days ago

ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

ImmunityBio Crashes On FDA Warning Over Anktiva Claims

Mar 24, 2026, 11:04 AM EDT - 22 days ago

ImmunityBio Crashes On FDA Warning Over Anktiva Claims

ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad

Mar 24, 2026, 10:53 AM EDT - 22 days ago

ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

Mar 20, 2026, 1:08 PM EDT - 26 days ago

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use

Mar 17, 2026, 1:54 PM EDT - 4 weeks ago

ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

Mar 17, 2026, 7:30 AM EDT - 4 weeks ago

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

Why Is ImmunityBio Stock Soaring On Friday?

Mar 13, 2026, 10:44 AM EDT - 4 weeks ago

Why Is ImmunityBio Stock Soaring On Friday?

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Mar 13, 2026, 7:30 AM EDT - 4 weeks ago

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug

Mar 9, 2026, 11:03 AM EDT - 5 weeks ago

ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

Mar 9, 2026, 7:30 AM EDT - 5 weeks ago

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

Feb 27, 2026, 7:30 AM EST - 6 weeks ago

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

ImmunityBio Investors Rally Behind Cancer Trial Milestone

Feb 26, 2026, 8:57 AM EST - 6 weeks ago

ImmunityBio Investors Rally Behind Cancer Trial Milestone

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Feb 26, 2026, 7:30 AM EST - 6 weeks ago

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Supersedes Expectations With Fivefold Revenue Increase

Feb 25, 2026, 1:02 PM EST - 7 weeks ago

ImmunityBio Supersedes Expectations With Fivefold Revenue Increase

ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate

Feb 25, 2026, 9:09 AM EST - 7 weeks ago

ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

Feb 23, 2026, 4:15 PM EST - 7 weeks ago

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth

Feb 23, 2026, 12:34 PM EST - 7 weeks ago

ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

Feb 23, 2026, 7:00 AM EST - 7 weeks ago

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

Feb 20, 2026, 8:30 AM EST - 7 weeks ago

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average

Feb 19, 2026, 11:37 AM EST - 7 weeks ago

ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average

ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

Feb 19, 2026, 9:00 AM EST - 7 weeks ago

ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

What's Behind The Jump In ImmunityBio Stock?

Feb 18, 2026, 12:02 PM EST - 2 months ago

What's Behind The Jump In ImmunityBio Stock?

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

Feb 18, 2026, 9:00 AM EST - 2 months ago

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

Feb 17, 2026, 6:07 AM EST - 2 months ago

ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More

Feb 2, 2026, 2:08 PM EST - 2 months ago

These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More

CAR KSS LCID CHH HIMS MARA MPT

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

Feb 2, 2026, 7:00 AM EST - 2 months ago

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

Jan 23, 2026, 7:00 AM EST - 2 months ago

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

Jan 20, 2026, 1:47 PM EST - 3 months ago

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

Alex2528
Alex2528 Apr. 16 at 9:11 AM
$IBRX shorts already shorting…
0 · Reply
Arztzeze
Arztzeze Apr. 16 at 9:07 AM
$IBRX who remembers the green candles ending december into january. When we were at 2. The daily small candles...i have a strong believe we are going into such daily greens again...the markets will look funny early ...then eventually produce a small daily green to end the day...i am in for the ride...FDA is exposed, the data speaks for itself, the revenue are coming strong...IL 15 is the standard and no other company does it better than IBRX.
0 · Reply
De12
De12 Apr. 16 at 9:04 AM
$IBRX $IOVA $ADMA Get that Greeen!!
0 · Reply
BeMarsh
BeMarsh Apr. 16 at 8:52 AM
$IBRX good morning from Kirtland Hills, Ohio
1 · Reply
CAVALRY_37748
CAVALRY_37748 Apr. 16 at 8:50 AM
$IBRX Good morning IBRX, From the looks of it the shorts are already trying to set it up to keep it below the 7.50 mark. Please stop buying options that you can't cash in on. It's clearly a manipulated market. If we all keep buying small amounts everyday we will win the price war. The produst is too good not to win. It could mean generational wealth.
0 · Reply
ghcb1981
ghcb1981 Apr. 16 at 8:47 AM
$IBRX
0 · Reply
Ulaughing
Ulaughing Apr. 16 at 8:37 AM
$IBRX Good morning you lovely people, and happy Thursdays. Me thinks today could be just a little bit spicy 🌶️ ❤️
0 · Reply
Marcanwin2025
Marcanwin2025 Apr. 16 at 8:18 AM
$IBRX Get your buys today in the "lit" market. It helps the charts. Call your broker.
0 · Reply
Dirtyhope
Dirtyhope Apr. 16 at 8:17 AM
$IBRX
0 · Reply
Nfty
Nfty Apr. 16 at 8:08 AM
$IBRX just getting started IL-15 reactivated stalled immunity, restoring cytokine sequencing, driving NK/CD8 response, clearing pathogens, and enabling tissue repair—transforming immune paralysis into coordinated, effective defense.
0 · Reply
Sp_Jesus
Sp_Jesus Apr. 16 at 8:02 AM
$IBRX WTH!
1 · Reply
Marcanwin2025
Marcanwin2025 Apr. 16 at 7:48 AM
$IBRX Shorts & dark pools work together to suppress tickets. Let's tune the lights on and go to a "lit" market. Change your broker if you have too. NFA
0 · Reply
MarCadoF
MarCadoF Apr. 16 at 7:47 AM
$IBRX Last 5 minutes trade will crack 8$ and more today
0 · Reply
MarCadoF
MarCadoF Apr. 16 at 7:41 AM
$IBRX Yes we will see 8$
1 · Reply
Marcanwin2025
Marcanwin2025 Apr. 16 at 7:38 AM
$IBRX Dark pool purchases don't help the charts, they help the shorts! NFA
0 · Reply
Marcanwin2025
Marcanwin2025 Apr. 16 at 7:26 AM
$IBRX Did you know that some trading platforms do not route to Nasdaq, the "lit"market? Citadel pays your broker for your order, they fill it and it goes to the dark pool. Citadel makes money from this and makes billions. Your buy order does not affect price discovery at all. It's sits in the dark and did nothing. Shorts need dark pools to suppress a stock. If buys were 90% lit it would be 10x harder to short the stock. Make sure your trading platform routes to Nasdaq in the lit market during market hours. Do your research.
0 · Reply
Marcanwin2025
Marcanwin2025 Apr. 16 at 7:10 AM
$IBRX Question has anyone here heard about PFOF.....payment for order flow? Do you know if your broker routes your buys to the dark pool or the lit market during market hours?
0 · Reply
Luke113
Luke113 Apr. 16 at 7:03 AM
$IBRX Besides not trusting Binance or Kraken plus the higher fees I don't mind my shares lending out to the shorts as long as this offers a good entry point for me and they are squeezed out of the short position later. It's part of the investment process. https://stocktwits.com/Intime32/message/650435828
1 · Reply
Nervet
Nervet Apr. 16 at 7:01 AM
$IBRX
0 · Reply
Alex2528
Alex2528 Apr. 16 at 7:00 AM
$IBRX good morning from London! Are you ready for exciting day ahead? 🌈
0 · Reply
Ostseemann
Ostseemann Apr. 16 at 6:44 AM
$IBRX Golden Cross 3J Chart is commmming ;)
0 · Reply
Luke113
Luke113 Apr. 16 at 6:35 AM
$IBRX What moves this stock upward: - science breakthroughs ❌ - landmark deals ❌ - moonshooting revenues ❌ - dog pictures ✅ Ironically it's the only thing shorts really fear. Like the vampires the garlic.
0 · Reply